Dawnrays Pharmaceutical (Holdings) Limited (2348.HK)

1.180 0.000 (0.00%) At close: 02:53PM HKT

Dawnrays Pharmaceutical (Holdings) Limited

CNT Tower
Units 3001-02 30th Floor 338 Hennessy Road
Wan Chai
Hong Kong
852 2111 9708
https://www.dawnrays.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 1,143

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Kei Ling Li	Co-Founder & Executive Chairman	1.16M	N/A	1949
Mr. Weixian Wu	Chief Executive Officer	3.38M	N/A	1969
Mr. Yung Lai Hung	Co-Founder & Executive Director	738.6k	N/A	1944
Mr. Yi Jun Wu	Chief Financial Officer	N/A	N/A	1964
Ms. Kit Ling Pang	Company Secretary	N/A	N/A	1966

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.

Description

Dawnrays Pharmaceutical (Holdings) Limited, an investment holding company, develops, manufactures, and sells non-patented pharmaceutical medicines in Mainland China and internationally. It operates in two segments, Intermediates and Bulk Medicines, and Finished Drugs. The company offers antibiotics, including pharmaceutical intermediates, bulk medicines, powder for injections, and oral antibiotics. It also provides and system specific medicines comprising cardiovascular systems; anti-allergic, anti-HBV, and digestive systems; urinary systems; and anti-pyretic analgesic, respiratory, and endocrine system drugs in the form of tablets, capsules, and granules. Dawnrays Pharmaceutical (Holdings) Limited was founded in 1995 and is headquartered in Wan Chai, Hong Kong.

Corporate governance

Dawnrays Pharmaceutical (Holdings) Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.